MARKET

MNPR

MNPR

Monopar Therapeutics Inc
NASDAQ

Real-time Quotes | Nasdaq Last Sale

7.88
+0.05
+0.57%
Opening 14:11 05/28 EDT
OPEN
8.11
PREV CLOSE
7.83
HIGH
8.11
LOW
7.80
VOLUME
1.52K
TURNOVER
--
52 WEEK HIGH
48.00
52 WEEK LOW
4.940
MARKET CAP
83.74M
P/E (TTM)
-20.9330
1D
5D
1M
3M
1Y
5Y

Analyst Rating

Based on 2 analysts

Buy

Disclaimer: The analysis information is for reference only and does not constitute an investment recommendation.

Analyst Price Target

The average MNPR stock price target is 41.00 with a high estimate of 42.00 and a low estimate of 40.00.

EPS

MNPR News

More
Monopar Therapeutics Q1 EPS $(0.100) Up From $(0.150) YoY
Monopar Therapeutics (NASDAQ:MNPR) reported quarterly losses of $(0.100) per share. This is a 33.33 percent increase over losses of $(0.150) per share from the same period last year.
Benzinga · 05/07 13:14
Monopar Therapeutics Reports First Quarter 2020 Financial Results and Business Updates
Monopar Therapeutics Inc. (Monopar or the Company) (MNPR), a clinical-stage biopharmaceutical company focused on developing proprietary therapeutics designed to extend life or improve the quality of life for cancer patients, today announced first quarter 2020
GlobeNewswire · 05/07 13:00
Monopar Therapeutics EPS misses by $0.06
seekingalpha · 03/27 18:20
Monopar Therapeutics Reports Fourth Quarter and Full-Year 2019 Financial Results and Business Updates
GlobeNewswire · 03/27 13:15
Brookline Capital Initiates Coverage On Monopar Therapeutics with Buy Rating, Announces $42 Price Target
Brookline Capital analyst Raja Kumaraguru initiates coverage on Monopar Therapeutics (NASDAQ:MNPR) with a Buy rating and a $42 price target.
Benzinga · 02/19 15:20
Monopar Therapeutics Reports Receives Orphan Drug Designation From EC For Camsirubicin In Treatment Of Soft Tissue Sarcoma
Benzinga · 02/18 14:07
Monopar Therapeutics Receives Orphan Drug Designation from the European Commission for Camsirubicin in the Treatment of Soft Tissue Sarcoma
GlobeNewswire · 02/18 14:00
JonesTrading Initiates Coverage On Monopar Therapeutics with Buy Rating
JonesTrading analyst Soumit Roy initiates coverage on Monopar Therapeutics (NASDAQ:MNPR) with a Buy rating.
Benzinga · 02/03 14:27

Industry

Biotechnology & Medical Research
+1.87%
Pharmaceuticals & Medical Research
+2.05%

Hot Stocks

Symbol
Price
%Change

About MNPR

Monopar Therapeutics Inc. is a clinical stage biopharmaceutical company. The Company is focused on developing therapeutics for cancer patients. Its pipeline includes Validive, Camsirubicin and MNPR-101. Validive is a clonidine mucobuccal tablet (clonidine MBT). Validive is designed to be used prophylactically to reduce the incidence, delay the time to onset, and decrease the duration of severe oral mucositis in patients undergoing chemoradiotherapy for oropharyngeal cancer. Its second product candidate, Camsirubicin, is a novel analog of doxorubicin. Camsirubicin is designed to reduce the cardiotoxic side effects generated by doxorubicin while retaining anti-cancer activity. MNPR-101 is a humanized monoclonal antibody designed to bind a specific cell surface receptor found on cancer cells, the urokinase plasminogen activator receptor (uPAR), and to interrupt several pathways required for tumor growth and progression. It is developing MNPR-101 for the treatment of advanced cancers.
More

Webull offers kinds of Monopar Therapeutics Inc stock information, including NASDAQ:MNPR real-time market quotes, financial reports, professional analyst ratings, in-depth charts, corporate actions, MNPR stock news, and many more online research tools to help you make informed decisions.